Close Menu

NEW YORK (GenomeWeb) – Twist Bioscience announced today that it has acquired Israeli synthetic biology software company Genome Compiler.

Under the terms of the agreement, the Genome Compiler research and development center in Israel will remain open as Twist's first international site. Financial terms of the deal were not disclosed.

Twist said it plans to use Genome Compiler's technology and expertise to develop a digital products portfolio, including an e-commerce solution with gene design capabilities, which is expected to be available in the second half of 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.